| Description |
ABMA is a novel broad-spectrum inhibitor of intracellular toxins and pathogens, efficiently protects cells against various toxins and pathogens including viruses, intracellular bacteria and parasite; protects mice from nasal instillation of an LD90 of ricin; provokes Rab7-positive late endosomal compartment accumulation in mammalian cells without affecting other organelles.
|
| Related Catalog |
|
| Target |
Intracellular bacteria[1] Viruses[1] Parasite[1]
|
| In Vitro |
ABMA protects cells against four bacterial toxins (Corynebacterium diphtheriae (DT; EC50 of 62.9 μM), Bacillus anthracis (LT), Clostridium difficile toxin B (TcdB; EC50 of 73.3 µM), Clostridium sordellii lethal toxin (TcsL; EC50 of 86.7 μM)), three viruses (Ebola (EC50 of 3.3 µM), rabies (EC50 of 19.4 µM), dengue-4 virus ( EC50 of 8.2 µM)), two species of Chlamydiales intracellular bacteria (Simkania negevensis and Chlamydia trachomatis), and the parasite Leishmania infantum (EC50 of 7.1 µM) at micromolar level[1]. In A549 cells, ABMA treatment induces a decrease in ricin cytotoxicity with an EC50 of 3.8 µM, and a protection factor (R) at 30 µM ranging from 5 to 10. ABMA retained almost 100% of its biological activity against ricin-induced cytotoxicity up to six days[1].
|
| In Vivo |
ABMA (2-200 mg/kg; intraperitoneal injection; female BALB/c mice) treatment protects mice from nasal instillation of an LD90 of ricin[1]. Animal Model: Pathogen-free female BALB/c mice (6 week-old) with ricin[1] Dosage: 2 mg/kg, 20 mg/kg, 200 mg/kg Administration: Intraperitoneal injection Result: A statistically significant protection according to survival curves was observed with a single ip dose of 2 mg/kg. The 20 mg/kg dose fully protected animals through to day 21. The 200 mg/kg dose resulted in 80% of protection of mice against ricin challenge with a single animal succumbing on day 15.
|
| References |
[1]. Wu Y, et al. ABMA, a small molecule that inhibits intracellular toxins and pathogens by interfering with late endosomal compartments. [2]. Wu Y, et al. DABMA: A Derivative of ABMA with Improved Broad-Spectrum Inhibitory Activity of Toxins and Viruses. ACS Med Chem Lett. 2019 Jul 2;10(8):1140-1147.
|
